Project Grant R42AG097334
Award Date 9/15/25
Completion Date 8/31/26
Dollars Obligated $506K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92121, USA
Similar Awards
- This federal Project Grant award of $152,237.00 was provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866). The grant supports research to investigate neuromuscular adaptation to exercise in the early stages of Alzheimer's disease (AD). The project aims to determine the neuromuscular adaptive response to endurance exercise training in AD mouse models before the onset of overt AD-like pathology. Key objectives include assessing mitochondrial...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $391,850 to support the development of a RUNX1 modulator therapy to slow cognitive decline in Alzheimer's disease (AD). The primary objectives are to: 1) optimize the safety and potency of a RUNX1-targeting antisense oligonucleotide (ASO) development candidate, and 2) demonstrate the efficacy of the RUNX1 ASO in a mouse model of AD using molecular biomarkers and behavioral endpoints. The goal is...
- This Project Grant award of $475,014.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a novel neurotrophic therapeutic for treating the cognitive deficits associated with Alzheimer's disease. The key products and services to be delivered through this grant include: Scaling up the production of a recombinant, non-erythropoietic neurotrophic protein that has demonstrated cognitive enhancement effects in Alzheimer's disease models. Evaluating the toxicity...
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $1,249,957 Project Grant under CFDA 93.866 (Aging Research) to Advantage Therapeutics, Inc. in Florida. The grant aims to perform IND-enabling studies on a small molecule that is disease-modifying, low-cost, and has a long safety record for the treatment of Alzheimer's disease. The proposed molecule is designed to reduce brain inflammation and restore phagocytosis, thereby improving the...
- The National Institute on Aging awarded a $1,198,947 Project Grant under the Aging Research program (CFDA 93.866) to The Regents of the University of California, San Francisco (UCSF) on September 30, 2023. The grant will fund research to investigate the neuroprotective effects of a blood-derived enzyme called GPLD1 on Alzheimer's disease pathology. Specifically, the project aims to: 1) examine the relationships between GPLD1, physical activity, immunovascular function, and cognition in older...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $994,436.00 to Transchromix LLC to develop novel brain-penetrant drugs for treating Alzheimer's disease (AD). The key products and services being delivered include: Discovering a noncanonical, translation regulatory function of the histone methyltransferase G9A in AD pathogenesis using a chromatin-activity-based chemoproteomic (ChAC) approach to dissect AD heterogeneity. Deducing the mechanism...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $372,400 to Nova Southeastern University to conduct research comparing the therapeutic potential of three compounds - tirzepatide, retatrutide, and crocetin - in mitigating Alzheimer's-like pathology in a mouse model of comorbid Alzheimer's disease and obesity/prediabetes. The 3-year study, running from December 2024 to November 2027, will assess the impact of these interventions on...
- This federal Project Grant award, valued at $1,552,000.00 and provided by the National Institute on Aging (CFDA 93.866 - Aging Research), supports a research study examining the relationship between markers of vascular and immune dysfunction, such as platelet aggregation and neutrophil levels, and their association with dementia risk and increased Alzheimer's disease (AD) biomarkers. The study, conducted by New York University School of Medicine, aims to integrate biofluid biomarker data with...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) is funding the development of novel ambroxol analogs as potential disease-modifying therapies for Alzheimer's disease and related dementias. The $496,600 award to Zywie LLC will be used to: 1) scale up manufacturing of two ambroxol analog compounds (ZW-002 and ZW-010) under non-GLP conditions, optimizing synthesis and validating analytical methods; 2) conduct short-term toxicology studies in healthy...